TRAVERE THERAPEUTICS, INC. Amortization of Intangible Assets
TRAVERE THERAPEUTICS, INC. (TVTX) reported Amortization of Intangible Assets of $3.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $3.80M, a 72.06% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $24.80M, a 100.00% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $17.71M, a 52.16% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $15.40M, a 42.59% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. amortization of intangible assets for fiscal 2025 was $59.21M, a 41.86% increase from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. amortization of intangible assets for fiscal 2024 was $41.74M, a 15.04% increase from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. amortization of intangible assets for fiscal 2023 was $36.28M, a 95.03% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. amortization of intangible assets for fiscal 2022 was $18.60M, a 68.41% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed | Amortization of Intangible Assets 28 month | Amortization of Intangible Assets 31 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.80M 10-Q · filed 2026-08-04 | $28.70M 10-Q · filed 2026-08-04 | $46.31M derived: sum of 3 quarters · filed 2026-08-04 | $61.71M derived: sum of 4 quarters · filed 2026-08-04 | ||||||
| 2026-03-31 | $24.80M 10-Q · filed 2026-05-04 | $42.51M derived: sum of 2 quarters · filed 2026-05-04 | $57.91M derived: sum of 3 quarters · filed 2026-05-04 | $71.51M derived: sum of 4 quarters · filed 2026-08-04 | ||||||
| 2025-12-31 | $17.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $33.11M derived: sum of 2 quarters · filed 2026-02-19 | $46.71M derived: sum of 3 quarters · filed 2026-08-04 | $59.21M 10-K · filed 2026-02-19 | ||||||
| 2025-09-30 | $15.40M 10-Q · filed 2025-10-30 | $29.00M derived: sum of 2 quarters · filed 2026-08-04 | $41.50M 10-Q · filed 2025-10-30 | $53.04M derived: sum of 4 quarters · filed 2026-08-04 | ||||||
| 2025-06-30 | $13.60M 10-Q · filed 2026-08-04 | $13.70M 10-Q · filed 2025-08-06 | $26.10M 10-Q · filed 2026-08-04 | $37.64M derived: sum of 3 quarters · filed 2026-08-04 | $48.44M derived: sum of 4 quarters · filed 2026-08-04 | |||||
| 2025-03-31 | $12.40M 10-Q · filed 2026-05-04 | $24.04M derived: sum of 2 quarters · filed 2026-05-04 | $34.84M derived: sum of 3 quarters · filed 2026-05-04 | $44.74M derived: sum of 4 quarters · filed 2026-05-04 | ||||||
| 2024-12-31 | $11.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $22.44M derived: sum of 2 quarters · filed 2026-02-19 | $32.34M derived: sum of 3 quarters · filed 2026-02-19 | $41.74M 10-K · filed 2026-02-19 | ||||||
| 2024-09-30 | $10.80M 10-Q · filed 2025-10-30 | $10.81M 10-Q · filed 2024-10-31 | $20.70M derived: sum of 2 quarters · filed 2025-10-30 | $30.10M 10-Q · filed 2025-10-30 | $30.06M 10-Q · filed 2024-10-31 | $39.02M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-06-30 | $9.90M 10-Q · filed 2025-08-06 | $9.90M 10-Q · filed 2024-08-01 | $19.20M 10-Q · filed 2025-08-06 | $19.25M 10-Q · filed 2024-08-01 | $28.22M derived: sum of 3 quarters · filed 2026-02-19 | $39.13M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-03-31 | $9.40M 10-Q · filed 2025-05-01 | $9.35M 10-Q · filed 2024-05-06 | $18.32M derived: sum of 2 quarters · filed 2026-02-19 | $29.23M derived: sum of 3 quarters · filed 2026-02-19 | $39.62M derived: sum of 4 quarters · filed 2026-02-19 | |||||
| 2023-12-31 | $8.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $19.83M derived: sum of 2 quarters · filed 2026-02-19 | $30.22M derived: sum of 3 quarters · filed 2026-02-19 | $36.28M 10-K · filed 2026-02-19 | ||||||
| 2023-09-30 | $10.91M 10-Q · filed 2024-10-31 | $21.30M derived: sum of 2 quarters · filed 2024-10-31 | $27.36M 10-Q · filed 2024-10-31 | $33.13M derived: sum of 4 quarters · filed 2025-02-21 | ||||||
| 2023-06-30 | $10.39M 10-Q · filed 2024-08-01 | $13.35M 10-Q · filed 2023-08-03 | $16.45M 10-Q · filed 2024-08-01 | $22.33M 10-Q · filed 2023-08-03 | $22.23M derived: sum of 3 quarters · filed 2025-02-21 | $27.31M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $6.06M 10-Q · filed 2024-05-06 | $8.99M 10-Q · filed 2023-05-04 | $11.84M derived: sum of 2 quarters · filed 2025-02-21 | $16.92M derived: sum of 3 quarters · filed 2025-02-21 | $24.49M derived: sum of 4 quarters · filed 2025-02-21 | |||||
| 2022-12-31 | $5.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $10.86M derived: sum of 2 quarters · filed 2025-02-21 | $18.43M derived: sum of 3 quarters · filed 2025-02-21 | $18.60M 10-K · filed 2025-02-21 | $30.96M 10-K · filed 2023-02-23 | |||||
| 2022-09-30 | $5.08M 10-Q · filed 2023-11-07 | $8.07M 10-Q · filed 2022-10-27 | $12.65M derived: sum of 2 quarters · filed 2023-11-07 | $12.82M 10-Q · filed 2023-11-07 | $22.20M 10-Q · filed 2022-10-27 | $11.82M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-06-30 | $7.57M 10-Q · filed 2023-08-03 | $14.13M 10-Q · filed 2023-08-03 | $6.74M derived: sum of 3 quarters · filed 2024-02-20 | $13.09M derived: sum of 4 quarters · filed 2024-02-20 | ||||||
| 2022-03-31 | $6.56M 10-Q · filed 2023-05-04 | -$830.00K derived: sum of 2 quarters · filed 2024-02-20 | $5.51M derived: sum of 3 quarters · filed 2024-02-20 | $11.65M derived: sum of 4 quarters · filed 2024-02-20 | ||||||
| 2021-12-31 | -$7.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$1.04M derived: sum of 2 quarters · filed 2024-02-20 | $5.09M derived: sum of 3 quarters · filed 2024-02-20 | $11.05M 10-K · filed 2024-02-20 | $24.95M 10-K · filed 2022-02-24 | |||||
| 2021-09-30 | $6.34M 10-Q · filed 2022-10-27 | $12.48M derived: sum of 2 quarters · filed 2022-10-27 | $18.43M 10-Q · filed 2022-10-27 | $24.39M derived: sum of 4 quarters · filed 2023-02-23 | ||||||
| 2021-06-30 | $6.14M 10-Q · filed 2022-08-04 | $12.09M 10-Q · filed 2022-08-04 | $18.04M derived: sum of 3 quarters · filed 2023-02-23 | $24.07M derived: sum of 4 quarters · filed 2023-02-23 | ||||||
| 2021-03-31 | $5.95M 10-Q · filed 2022-05-05 | $11.91M derived: sum of 2 quarters · filed 2023-02-23 | $17.93M derived: sum of 3 quarters · filed 2023-02-23 | $23.21M derived: sum of 4 quarters · filed 2023-02-23 | ||||||
| 2020-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $11.98M derived: sum of 2 quarters · filed 2023-02-23 | $17.26M derived: sum of 3 quarters · filed 2023-02-23 | $22.44M 10-K · filed 2023-02-23 | ||||||
| 2020-09-30 | $6.02M 10-Q · filed 2021-10-29 | $11.31M derived: sum of 2 quarters · filed 2021-10-29 | $16.48M 10-Q · filed 2021-10-29 | $21.59M derived: sum of 4 quarters · filed 2022-02-24 | ||||||
| 2020-06-30 | $5.29M 10-Q · filed 2021-07-29 | $10.46M 10-Q · filed 2021-07-29 | $15.57M derived: sum of 3 quarters · filed 2022-02-24 | $20.58M derived: sum of 4 quarters · filed 2022-02-24 | ||||||
| 2020-03-31 | $5.17M 10-Q · filed 2021-05-06 | $10.29M derived: sum of 2 quarters · filed 2022-02-24 | $15.29M derived: sum of 3 quarters · filed 2022-02-24 | $20.15M derived: sum of 4 quarters · filed 2022-02-24 | ||||||
| 2019-12-31 | $5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $10.12M derived: sum of 2 quarters · filed 2022-02-24 | $14.98M derived: sum of 3 quarters · filed 2022-02-24 | $19.71M 10-K · filed 2022-02-24 | ||||||
| 2019-09-30 | $5.01M 10-Q · filed 2020-11-05 | $9.86M derived: sum of 2 quarters · filed 2020-11-05 | $14.59M 10-Q · filed 2020-11-05 | $19.30M derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2019-06-30 | $4.86M 10-Q · filed 2020-07-31 | $9.59M 10-Q · filed 2020-07-31 | $14.30M derived: sum of 3 quarters · filed 2021-03-01 | $18.92M derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2019-03-31 | $4.73M 10-Q · filed 2020-05-11 | $9.44M derived: sum of 2 quarters · filed 2021-03-01 | $14.06M derived: sum of 3 quarters · filed 2021-03-01 | $18.56M derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2018-12-31 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $9.33M derived: sum of 2 quarters · filed 2021-03-01 | $13.83M derived: sum of 3 quarters · filed 2021-03-01 | $18.03M 10-K · filed 2021-03-01 | ||||||
| 2018-09-30 | $4.63M 10-Q · filed 2019-10-30 | $9.12M derived: sum of 2 quarters · filed 2019-10-30 | $13.32M 10-Q · filed 2019-10-30 | $17.65M derived: sum of 4 quarters · filed 2020-02-24 | ||||||
| 2018-06-30 | $4.50M 10-Q · filed 2019-08-06 | $8.69M 10-Q · filed 2019-08-06 | $13.03M derived: sum of 3 quarters · filed 2020-02-24 | $17.54M derived: sum of 4 quarters · filed 2020-02-24 | ||||||
| 2018-03-31 | $4.20M 10-Q · filed 2019-05-07 | $8.53M derived: sum of 2 quarters · filed 2020-02-24 | $13.04M derived: sum of 3 quarters · filed 2020-02-24 | $17.36M derived: sum of 4 quarters · filed 2020-02-24 | ||||||
| 2017-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $8.84M derived: sum of 2 quarters · filed 2020-02-24 | $13.16M derived: sum of 3 quarters · filed 2020-02-24 | $17.33M 10-K · filed 2020-02-24 | ||||||
| 2017-09-30 | $4.51M 10-Q · filed 2018-11-01 | $8.82M derived: sum of 2 quarters · filed 2018-11-01 | $13.00M 10-Q · filed 2018-11-01 | $17.13M derived: sum of 4 quarters · filed 2019-02-26 | ||||||
| 2017-06-30 | $4.32M 10-Q · filed 2018-08-03 | $8.49M 10-Q · filed 2018-08-03 | $12.62M derived: sum of 3 quarters · filed 2019-02-26 | $16.69M derived: sum of 4 quarters · filed 2019-02-26 | ||||||
| 2017-03-31 | $4.17M 10-Q · filed 2018-07-06 | $8.30M derived: sum of 2 quarters · filed 2019-02-26 | $12.37M derived: sum of 3 quarters · filed 2019-02-26 | $16.28M derived: sum of 4 quarters · filed 2019-02-26 | ||||||
| 2016-12-31 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $8.20M derived: sum of 2 quarters · filed 2019-02-26 | $12.11M derived: sum of 3 quarters · filed 2019-02-26 | $15.99M 10-K · filed 2019-02-26 | ||||||
| 2016-09-30 | $4.07M 10-Q · filed 2017-11-07 | $7.98M derived: sum of 2 quarters · filed 2017-11-07 | $11.86M 10-Q · filed 2017-11-07 | $15.68M derived: sum of 4 quarters · filed 2018-07-06 | ||||||
| 2016-06-30 | $3.91M 10-Q · filed 2017-08-09 | $7.79M 10-Q · filed 2017-08-09 | $11.61M derived: sum of 3 quarters · filed 2018-07-06 | $15.48M derived: sum of 4 quarters · filed 2018-07-06 | ||||||
| 2016-03-31 | $3.88M 10-Q · filed 2017-05-05 | $7.70M derived: sum of 2 quarters · filed 2018-07-06 | $11.57M derived: sum of 3 quarters · filed 2018-07-06 | $15.38M derived: sum of 4 quarters · filed 2018-07-06 | ||||||
| 2015-12-31 | $3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | $7.69M derived: sum of 2 quarters · filed 2018-07-06 | $11.50M derived: sum of 3 quarters · filed 2018-07-06 | $13.23M 10-K · filed 2018-07-06 | ||||||
| 2015-09-30 | $3.88M 10-Q · filed 2016-11-04 | $7.68M derived: sum of 2 quarters · filed 2016-11-04 | $9.42M 10-Q · filed 2016-11-04 | $11.23M derived: sum of 4 quarters · filed 2017-03-01 | ||||||
| 2015-06-30 | $3.81M 10-Q · filed 2016-08-05 | $5.54M 10-Q · filed 2016-08-05 | $7.35M derived: sum of 3 quarters · filed 2017-03-01 | $9.17M derived: sum of 4 quarters · filed 2017-03-01 | ||||||
| 2015-03-31 | $1.74M 10-Q · filed 2016-05-05 | $3.81M 10-Q · filed 2015-08-10 | $3.55M derived: sum of 2 quarters · filed 2017-03-01 | $5.36M derived: sum of 3 quarters · filed 2017-03-01 | $6.90M derived: sum of 4 quarters · filed 2017-03-01 | |||||
| 2014-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $3.63M derived: sum of 2 quarters · filed 2017-03-01 | $5.16M derived: sum of 3 quarters · filed 2017-03-01 | $5.28M 10-K · filed 2017-03-01 | ||||||
| 2014-09-30 | $1.81M 10-Q · filed 2015-11-06 | $3.35M derived: sum of 2 quarters · filed 2015-11-06 | $3.47M 10-Q · filed 2015-11-06 | $3.64M derived: sum of 4 quarters · filed 2016-02-26 | ||||||
| 2014-06-30 | $1.54M 10-Q · filed 2015-08-10 | $1.65M 10-Q · filed 2015-08-10 | $1.82M derived: sum of 3 quarters · filed 2016-02-26 | $1.88M derived: sum of 4 quarters · filed 2016-02-26 | ||||||
| 2014-03-31 | $113.97K 10-Q · filed 2014-05-15 | $286.44K derived: sum of 2 quarters · filed 2016-02-26 | $337.50K derived: sum of 3 quarters · filed 2016-02-26 | $388.01K derived: sum of 4 quarters · filed 2016-02-26 | ||||||
| 2013-12-31 | $172.47K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $223.53K derived: sum of 2 quarters · filed 2016-02-26 | $274.05K derived: sum of 3 quarters · filed 2016-02-26 | $324.00K 10-K · filed 2016-02-26 | ||||||
| 2013-09-30 | $51.06K 10-Q · filed 2013-11-13 | $101.58K derived: sum of 2 quarters · filed 2013-11-13 | $151.53K 10-Q · filed 2013-11-13 | $272.91K 10-Q · filed 2013-11-13 | ||||||
| 2013-06-30 | $50.51K 10-Q · filed 2013-09-16 | $100.47K 10-Q · filed 2013-09-16 | $221.85K 10-Q · filed 2013-09-16 | |||||||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-15 | $49.95K 10-Q · filed 2013-07-24 | ||||||||
| 2012-09-30 | $34.88K 10-Q · filed 2013-11-13 | $71.47K derived: sum of 2 quarters · filed 2013-11-13 | $71.47K 10-Q · filed 2013-11-13 | |||||||
| 2012-06-30 | $36.58K 10-Q · filed 2013-09-16 | $36.58K 10-Q · filed 2013-09-16 | ||||||||
| 2012-03-31 | $0.00 10-Q/A · filed 2013-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |